Tal Zaks Biography and Net Worth

Insider of Moderna

Tal Zvi Zaks is the chief medical officer of Moderna.

Dr. Zaks joined Moderna—now famous for its COVID-19 vaccine—back in 2015 when it was still considered a preclinical biotech company. With the emergence of a global pandemic in 2019, Moderna quickly shifted from pre-clinical to a full-on commercial entity as it developed the COVID-19 vaccine. Shortly after this pivot, in September 2021, Dr. Zaks announced his intention to leave the company.

Directly prior to Moderna, Dr. Zaks spent over four years in senior development positions with Sanofi, first as vice president and head of development for the company’s oncology division and then as its senior vice president and head of Sanofi Oncology. In these roles, Dr. Zaks oversaw all aspects of development, commercialization and drug discovery for the oncology division.

Dr. Zaks launched his industry career at GlaxoSmithKline in 2004 as director of clinical development and translational medicine in the genetics research group. He has also spent time practicing medicine in a variety of institutions, including the National Cancer Institute, Temple University Hospital, the University of Pennsylvania School of Medicine and the VA Medical Center.

Dr. Zaks currently serves as an adjunct associate professor of medicine at Pennsylvania University’s school of medicine and as a non-executive director at Adaptimmune US. He completed his M.D. and Ph.D. from Ben Gurion University in Israel and conducted his post-doctoral research at the U.S. National Institutes of Health.

What is Tal Zvi Zaks' net worth?: The estimated net worth of Tal Zvi Zaks is at least $205,550.00 as of June 30th, 2021. Dr. Zaks owns 5,000 shares of Moderna stock worth more than $205,550 as of November 23rd. This net worth evaluation does not reflect any other assets that Dr. Zaks may own. Learn More about Tal Zvi Zaks' net worth.
How do I contact Tal Zvi Zaks?: The corporate mailing address for Dr. Zaks and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Tal Zvi Zaks' contact information.
Has Tal Zvi Zaks been buying or selling shares of Moderna?: Tal Zvi Zaks has not been actively trading shares of Moderna during the past quarter. Most recently, Tal Zvi Zaks sold 5,000 shares of the business's stock in a transaction on Wednesday, June 30th. The shares were sold at an average price of $237.00, for a transaction totalling $1,185,000.00. Following the completion of the sale, the insider now directly owns 5,000 shares of the company's stock, valued at $1,185,000. Learn More on Tal Zvi Zaks' trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (Chief Executive Officer), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 46 times. They sold a total of 646,276 shares worth more than $81,357,882.30. The most recent insider tranaction occured on October, 7th when CFO James M Mock sold 715 shares worth more than $42,985.80. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 10/7/2024.

Tal Zvi Zaks Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/30/2021	Sell	5,000	$237.00	$1,185,000.00	5,000
6/16/2021	Sell	5,000	$200.00	$1,000,000.00	5,000
6/9/2021	Sell	5,000	$212.30	$1,061,500.00	5,000
5/26/2021	Sell	5,000	$168.70	$843,500.00	5,000
5/19/2021	Sell	5,000	$155.74	$778,700.00	5,000
5/10/2021	Sell	3,670	$158.48	$581,621.60	3,670
4/12/2021	Sell	5,000	$138.96	$694,800.00	5,000
4/5/2021	Sell	5,000	$129.71	$648,550.00	5,000
3/22/2021	Sell	1,199	$144.82	$173,639.18	1,199
3/15/2021	Sell	10,034	$140.68	$1,411,583.12	10,000
1/25/2021	Sell	5,000	$143.12	$715,600.00	5,000
1/19/2021	Sell	5,000	$123.88	$619,400.00	5,000
12/28/2020	Sell	1,200	$116.27	$139,524.00	1,200
12/21/2020	Sell	17,129	$142.59	$2,442,424.11	10,000
12/14/2020	Sell	25,034	$157.81	$3,950,615.54	10,000
11/30/2020	Sell	20,000	$147.76	$2,955,200.00	5,000
11/23/2020	Sell	15,000	$100.53	$1,507,950.00	5,000
11/16/2020	Sell	15,000	$96.99	$1,454,850.00	5,000
10/26/2020	Sell	15,000	$70.00	$1,050,000.00	5,000
10/19/2020	Sell	15,000	$71.94	$1,079,100.00	5,000
10/12/2020	Sell	15,000	$74.47	$1,117,050.00	5,000
10/5/2020	Sell	15,000	$70.24	$1,053,600.00	5,000
9/28/2020	Sell	17,197	$70.28	$1,208,605.16	7,197
9/21/2020	Sell	20,000	$67.30	$1,346,000.00	10,000
9/14/2020	Sell	20,034	$62.66	$1,255,330.44	10,000
9/8/2020	Sell	26,467	$56.20	$1,487,445.40	10,000
8/31/2020	Sell	30,000	$64.10	$1,923,000.00
8/24/2020	Sell	25,000	$64.99	$1,624,750.00	10,000
8/17/2020	Sell	20,000	$69.06	$1,381,200.00	10,000
7/27/2020	Sell	20,000	$78.73	$1,574,600.00	10,000
7/20/2020	Sell	20,000	$83.50	$1,670,000.00	10,000
7/13/2020	Sell	20,000	$69.94	$1,398,800.00	10,000
7/7/2020	Sell	62,688	$59.26	$3,714,890.88	22,936
6/30/2020	Sell	39,752	$64.00	$2,544,128.00	24,121
6/23/2020	Sell	39,752	$63.71	$2,532,599.92	24,121
6/16/2020	Sell	39,752	$63.76	$2,534,587.52	24,121
6/2/2020	Sell	98,956	$58.32	$5,771,113.92	11,467
5/26/2020	Sell	125,044	$66.54	$8,320,427.76	42,570
5/5/2020	Sell	4,770	$50.48	$240,789.60
4/24/2020	Sell	10,000	$47.15	$471,500.00	4,770
4/17/2020	Sell	10,000	$48.81	$488,100.00	14,770
4/13/2020	Sell	10,000	$32.00	$320,000.00	24,770
4/3/2020	Sell	10,000	$32.81	$328,100.00	34,770
3/27/2020	Sell	10,000	$28.37	$283,700.00	44,770
3/20/2020	Sell	10,000	$29.13	$291,300.00	54,770
12/12/2019	Sell	100,000	$18.54	$1,854,000.00	104,770

Tal Zvi Zaks Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $41.11

$37.76

$42.40

50 Day Range

MA: $54.96

$36.85

$71.99

2 Week Range

Now: $41.11

$35.80

$170.47

Volume

13,410,793 shs

Average Volume

9,553,876 shs

Market Capitalization

$15.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

New post-election stock warning from Wall Street

From Chaikin Analytics | Ad

If you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first time in history...

Not everything is as rosy as it seems on Wall Street.